Kairos Pharma (KAPA) EBITDA (2023 - 2025)

Kairos Pharma (KAPA) has reported EBITDA for 3 consecutive years, with -$1.5 million the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, EBITDA fell 555.86% year-over-year to -$1.5 million; the trailing twelve-month figure through Jun 2025 stood at -$4.6 million (down 141.43% YoY), and the FY2025 full-year result was -$5.6 million, down 137.81% from the prior year.
• EBITDA fell to -$1.5 million in Q2 2025 per KAPA's latest filing, from -$1.3 million in the prior quarter.
• Across five years, EBITDA topped out at -$222000.0 in Q2 2024 and bottomed at -$1.5 million in Q2 2025.
• Historically, EBITDA has averaged -$804500.0 across 3 years, with a median of -$736000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA slumped 32.78% in 2024, then sank 555.86% in 2025.
• Over 3 years, EBITDA stood at -$1.1 million in 2023, then slumped by 32.78% to -$1.4 million in 2024, then retreated by 0.69% to -$1.5 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$1.5 million, -$1.3 million, and -$1.4 million for Q2 2025, Q1 2025, and Q4 2024 respectively.